Cannabis Law Report

SEPTEMBER 24, 2019

billion by the end of 2025, according to a new report by Grand View Research, Inc. Increasing need for pain management therapies and growing disease burden of chronic pain among elders is also expected to boost demand. from 2019 to 2025. from 2019 to 2025. from 2019 to 2025. Chronic Pain.

Chronic Pain 40

Chronic Pain Legalization Marijuana Pharmaceutical 40

The Joint Blog

NOVEMBER 21, 2022

While some are quick to criticize it and point out its allegedly adverse effects, habitual users swear by it as an often miracle cure for a plethora of conditions. Indeed, only in the United States, it is projected to hit $16 billion by 2025. Pain management . Cannabis consumption is still a polarizing topic.

Consumption 52

Consumption CBD Research and Development Topical 52

Cannabis Law Report

JANUARY 5, 2022

The issued claims protect the use of MYMD-1 in a method of treatment for the progressive and generalized loss of skeletal muscle mass and strength known as sarcopenia. MYMD-1 also shows promise in pre-clinical studies as a potential treatment for post- COVID-19 complications and as an anti-fibrotic and anti-proliferation therapeutic.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

NOVEMBER 16, 2021

Our treatment designed for delaying aging has a distinctive drug profile of oral delivery, selectivity, and very low toxicity as compared with TNF blockers, all of which are delivered by injection only. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

SEPTEMBER 13, 2021

Commenting on the size and scope of the market for delaying aging, Dr. Chapman added, “There are no FDA-approved drugs for treating aging disorders and extending healthy lifespan in humans, a market expected to be at least $600 billion by 2025 1 according to a major investment bank.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Cannabis Law Report

OCTOBER 20, 2019

It is also the first FDA approved drug for the treatment of patients with Dravet syndrome. The pharmaceutical industry would likely have significant opportunities to develop new cannabinoid-based drugs for a multitude of medical conditions now being addressed by medical marijuana. billion in federal tax revenue between 2017 and 2025.

Marijuana 45

Marijuana Pharmaceutical Chronic Pain Research and Development 45

Cannabis Law Report

FEBRUARY 18, 2020

Researchers predict that the market will be valued at $7 billion by the year 2025. And according to a Nielsen analytical report , the US market of legal marijuana will reach $41 billion in revenue by 2025, meaning that New York will make up close to 17% of the market share. In 2018, the New York legal cannabis market reached $1.8

Marijuana 59

Marijuana Consumption Dispensary Vaping 59